CytoMed Therapeutics Overview
Latest ROE for CytoMed Therapeutics: -63.27% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-63.27%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
CytoMed Therapeutics (GDTC) currently reports a ROE of -63.27%. That is below the sector sector average of -5.87%. Use the charts on this page to explore CytoMed Therapeutics's ROE history and peer comparisons.
CytoMed Therapeutics's ROE of -63.27% is lower than the its sector sector average of -5.87%. That is roughly 978.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but CytoMed Therapeutics's current -63.27% should be judged against industry norms (sector average: -5.87%) and against GDTC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -63.27%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.87%. From there, open related valuation or income-statement pages for CytoMed Therapeutics, and consider following GDTC for alerts when major investors trade the stock.
